Unlocking Q1 Potential of Ventas (VTR): Exploring Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Ventas (VTR) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
What's in the Offing for Ventas Stock This Earnings Season?
While VTR's Q1 earnings are likely to have benefited from favorable SHOP operating trends and a well-diversified tenant base, high interest expenses may have hurt it.
Ventas (VTR) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?
Ventas Stock Surges 13.9% in Three Months: Will the Trend Last?
Aging population, rising healthcare expenses, favorable outpatient visit trends and accretive investments in its research portfolio are likely to support VTR.
This is Why Ventas (VTR) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?
Why Ventas Is Poised For Strong Long-Term Returns
Ventas is a well-run REIT that's experiencing high growth, particularly in its SHOP portfolio. It carries a strong balance sheet and management has resumed meaningful dividend growth. The recent dip in price has brought the yield to 3%. Combined with high single digit FFO/share growth, VTR could deliver potential market-beating total returns.
Here's Why You Should Retain Ventas Stock in Your Portfolio Now
Rising healthcare expenditures and an aging population support VTR's senior housing operating portfolio despite competition and tenant concentration risks.
Ventas (VTR) Up 2.2% Since Last Earnings Report: Can It Continue?
Ventas (VTR) reported earnings 30 days ago. What's next for the stock?
Key Reasons to Add Ventas Stock to Your Portfolio Right Now
VTR is set to gain from rising healthcare spending amid an aging population. Accretive investments in the research portfolio and solid balance sheet bode well.
Ventas Stock Gains 14.1% in Three Months: Will the Trend Last?
VTR is likely to gain from an aging population, rising healthcare expenses, favorable outpatient visit trends and accretive investments in its research portfolio.
Ventas, Inc. (VTR) Presents at Citi 2025 Global Property CEO Conference (Transcript)
Ventas, Inc. (NYSE:VTR ) Citi 2025 Global Property CEO Conference March 4, 2025 1:30 PM ET Company Participants Debra Cafaro - Chief Executive Officer Justin Hutchens - Executive Vice President-Senior Housing & Chief Investment Officer Bob Probst - Executive Vice President & Chief Financial Officer Conference Call Participants Nick Joseph - Citi Michael Griffin - Citi Nick Joseph Welcome to Citi's 2025 Global Property CEO Conference. I'm Nick Joseph here with Michael Griffin with Citi Research.
All You Need to Know About Ventas (VTR) Rating Upgrade to Buy
Ventas (VTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
